Post-market surveillance, run as a service.
The obligations that start after approval are the ones that revoke approvals when neglected. Our PMS retainer keeps complaints, vigilance reporting, distribution records and recall readiness handled every month — audit-ready always.
Registration ends. The obligation doesn’t.
Post-market surveillance (PMS) is the set of duties that continue for as long as a device stays on the Malaysian market — after it is registered with the MDA and your business is licensed to trade it. Under the Medical Device Act 2012 (Act 737) and the Medical Device Regulations 2012, the establishment holding the registration and licence must keep watching the device in real-world use, capture what goes wrong, and act on it — not once a year, but continuously.
In practice that means five things the MDA and your GDPMD auditors expect to see running: complaint handling, distribution records and lot traceability (increasingly tied to UDI — unique device identification), Mandatory Problem Reporting (MPR) of adverse events and incidents to the MDA, and Field Safety Corrective Actions (FSCA) or recalls when a safety issue emerges. The registration holder — or, for a foreign manufacturer, the authorized representative — is the MDA’s vigilance point of contact for all of it.

Compliance that has to happen monthly cannot be bought annually
Every GDPMD and licence audit asks the same questions: where are your complaint records, can you trace this lot to its customers, who decided this incident was not reportable — and on what criteria? Companies that treat these as audit-week paperwork fail them; companies that run them monthly barely notice the audit.
PMS-as-a-service is our answer: a fixed monthly retainer under which we operate the post-market system with your team — the same consultant, month after month, who already knows your devices, your distributors and your history. It pairs naturally with the AR retainer for foreign manufacturers and the GDPMD monthly plan for local distributors, and folds cleanly into a manufacturer’s existing ISO 13485 quality system where one is in place.
What we run for you
- Complaint intake, register and investigation records
- Incident triage against mandatory problem reporting criteria — same-day
- Mandatory problem reports (MPR) drafted and submitted to the MDA
- Distribution records and lot traceability kept current (UDI-ready)
- FSCA / recall procedures tested and ready; full coordination if triggered
- Periodic PMS summaries for management review and audits

How the engagement runs
- PMS review — we assess your existing complaint, traceability and reporting procedures against your Act 737 duties; you receive a findings report and a scoped monthly quote.
- System build or repair — procedures, complaint and distribution registers, MPR templates and a tested FSCA/recall SOP, tailored to your portfolio and trained into your team.
- Monthly operation — we run the registers, triage incidents the day they surface, draft and submit any mandatory problem reports, and keep distribution and lot traceability current.
- Audit & review support — periodic PMS summaries for management review, and we stand with you at GDPMD surveillance audits and licence renewals so the evidence is already there when the auditor asks.
What a PMS retainer costs
PMS is an ongoing obligation, so it is priced as an ongoing retainer — a fixed monthly fee scoped to your device portfolio, complaint volume and number of distributors, not a one-off project fee. Because scope varies this much between a single-product distributor and a multi-brand importer, PMS retainers are quoted separately rather than list-priced.
The retainer slots alongside the published, all-inclusive renewal schedule that keeps the rest of your file alive — GDPMD / ISO 13485 certificate RM2,500/yr, establishment licence RM9,000 every 3 years and product registration RM6,000 every 5 years — all held on one calendar for you. See the full pricing schedule for the market-entry and renewal figures; we add your PMS retainer as a scoped monthly line.
Get a scoped PMS quoteApakah kewajipan pengawasan pasca-pasaran (PMS) di bawah Akta Peranti Perubatan?
Selepas peranti didaftarkan dengan MDA di bawah Akta Peranti Perubatan 2012 (Akta 737), pemegang pendaftaran, pengimport, pengedar dan wakil sah wajib meneruskan pengawasan pasca-pasaran: mengendalikan aduan, menyimpan rekod pengedaran dan kemampuan surih lot, serta melaporkan kejadian buruk kepada MDA melalui Laporan Masalah Mandatori (MPR) dalam tempoh yang ditetapkan. Kewajipan ini termasuk tindakan pembetulan keselamatan lapangan (FSCA) dan penarikan balik (recall) apabila perlu, dan ia berjalan selagi peranti berada di pasaran. Retainer PMS bulanan kami menjalankan sistem ini bersama pasukan anda supaya sentiasa sedia diaudit — WhatsApp 010-206 2070 untuk sebut harga.
A named consultant who already knows your devices
Regulatory consulting is an unregulated trade — anyone can print the title on a card. The person who triages your incidents and signs off your reports to the MDA is named here, with a LinkedIn profile you can check.

Evin Lim
Advises from the operator’s chair — the group registers, imports and supplies devices itself — and speaks on the Malaysian pharmaceutical and device industry on BERNAMA TV and RTM.
LinkedIn profileLim Yen Thong
Your first point of contact for scope, timelines and quotations. Lim Yen Thong runs the commercial side of the device practice and coordinates every engagement from first enquiry to signed proposal.
LinkedIn profileFrequently asked questions
What post-market duties do device companies have in Malaysia?
What does the PMS retainer include?
Who is legally responsible for post-market surveillance — us or the manufacturer?
We have never had a complaint — do we still need PMS?
How fast must incidents be reported to the MDA?
What is an FSCA or recall, and would you run it for us?
Does post-market surveillance affect our GDPMD certificate or licence renewal?
When did someone last check your complaint register?
If the honest answer is 'before the last audit', a monthly retainer costs less than the finding it prevents — and far less than a recall run without a system behind it.